Stocktoria

Pluri Inc. PLUR

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2007-12-10

Pluri Inc. financials (annual)

Revenue
$2.8M $50000 $54000 $23000 $234000 $287000 $326000 $1.3M 2016201720182019202020212022202320242025
Net income
-$23.2M -$27.8M -$26.1M -$35.3M -$29.2M -$49.9M -$41.2M -$28.3M -$20.9M -$22.6M 2016201720182019202020212022202320242025
Free cash flow
-$20.3M -$22.0M -$21.7M -$29.7M -$26.6M -$31.3M -$36.8M -$23.1M -$18.3M -$19.8M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$1.3M$326,000$287,000$234,000$23,000$54,000$50,000$2.8M
Gross profit$654,000$322,000$278,000$234,000$23,000$52,000$48,000$2.7M
R&D expense$12.9M$12.4M$15.7M$24.6M$30.5M$23.1M$29.9M$26.4M$24.0M$22.9M
Operating income-$22.2M-$22.2M-$27.2M-$41.6M-$50.6M-$29.5M-$35.5M-$33.7M-$28.0M-$23.3M
Interest expense$843,000$887,000$78,000
Income tax-$5,000
Net income-$22.6M-$20.9M-$28.3M-$41.2M-$49.9M-$29.2M-$35.3M-$26.1M-$27.8M-$23.2M
EPS (diluted)$-3.56$-3.99$-6.24$-1.28$-1.77
Operating cash flow-$18.2M-$18.0M-$22.9M-$36.5M-$30.9M-$26.4M-$29.5M-$21.4M-$21.6M-$18.5M
Free cash flow-$19.8M-$18.3M-$23.1M-$36.8M-$31.3M-$26.6M-$29.7M-$21.7M-$22.0M-$20.3M
Cash & equivalents$5.9M$6.8M$5.4M$9.8M$31.2M$8.3M$4.1M$8.8M$4.7M$6.2M
Total assets$38.7M$39.5M$50.8M$68.1M$93.5M$65.5M$31.3M$39.0M$37.5M$45.9M
Shareholders' equity-$6.8M$5.4M$15.3M$32.2M$57.2M$56.1M$21.8M$28.5M$30.3M$38.2M

Growth · year-over-year · Revenue CAGR -10.2%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth+309.8%+13.6%+22.6%-57.4%+8.0%+651.2%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.